161 results on '"Germing U"'
Search Results
2. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
3. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
4. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
6. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
7. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
8. The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T
9. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
10. Topic: AS02-Epidemiology
11. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
12. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
13. Protein expression and clinical significance of the NEDDylation pathway in myelodysplastic syndrome
14. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
15. Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes
16. Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients
17. Impact of Red Blood Cell Transfusions on Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS (EUMDS) Registry
18. Lymphocytosis, Neutrophil/Lymphocyte Ratio and Monocyte/Lymphocyte Ratio as Prognostic Markers in CMML
19. Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry
20. Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance
21. Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML
22. Dichotomous Synexpression of Fanconi Anemia/BRCA1 Pathway Proteins in Myelodysplastic Syndromes
23. Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
24. Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival
25. Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the Pace Study
26. Validation of a New Clinically Based Classification System for Stratification of Prognosis in Patients with CMML
27. Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups
28. Peripheral Blood WT1 Expression Refines Prognostic Information for MDS Patients Within the IPSS-R Risk Categories Very Low, Low and Intermediate
29. It is Easix to Predict Mortality of Low Risk MDS Patients
30. RNA Sequencing Reveals TGF Beta Mediated Functional Inhibition of Mesenchymal Stromal Cells in MDS
31. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
32. Increased Serum Ferritin and Genetic Instability in Myelodysplastic Syndromes
33. Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure
34. 240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE
35. 295 IDIOPATHIC CYTOPENIA OF UNKNOWN SIGNIFICANCE (ICUS) AND IDIOPATHIC DYSPLASIA OF UNKNOWN SIGNIFICANCE (IDUS): A MULTI-CENTER REGISTRY STUDY
36. 318 THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)
37. 245 CHOICE OF THERAPY HAS THE STRONGEST IMPACT ON SURVIVAL IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA OR AML AFTER MYELODYSPLASTIC SYNDROME
38. 72 PERSONALIZED TREATMENT APPROACH FOR GFI136N HETEROZYGOUS OR HOMOZYGOUS MDS PATIENTS
39. 119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP
40. 231 UPDATE OF RESPONSE TO TREATMENT WITH AZACITIDINE AND DECITABINE IN HIGH-RISK MDS PATIENTS FROM THE DUESSELDORF MDS REGISTRY – 10 YEARS EXPERIENCE WITH HYPOMETHYLATING TREATMENT
41. 51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY
42. 162 THE PRESENCE OF SUBCLONES WITHIN AN ABNORMAL KARYOTYPE IS ASSOCIATED WITH AN INFERIOR PROGNOSIS IN MDS PATIENTS
43. 81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES
44. 264 MMP-9 SERUM LEVEL IN MDS DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION
45. 121 PERIPHERAL BLOOD (PB) WILMS' TUMOR 1 (WT1) EXPRESSION QUANTIFIED BY A STANDARDIZED EUROPEAN LEUKEMIA NET (ELN)-CERTIFIED ASSAY AS PROGNOSTIC AND MINIMAL RESIDUAL DISEASE (MRD) MARKER IN MDS
46. 53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
47. 160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
48. 317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS
49. 37 CAR, A NOVEL MEDIATOR OF ERYTHROID DIFFERENTIATION AND MIGRATION, IS SPECIFICALLY DOWNREGULATED IN ERYTHROPOIETIC PROGENITOR CELLS IN MDS
50. 120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.